Praxis Precision Medicines (PRAX) vs Summit Therapeutics (SMMT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Praxis Precision Medicines (PRAX) has outperformed Summit Therapeutics (SMMT) over the past year, gaining 76.9% versus a loss of 38.5%. Over five years, SMMT leads with a +92.8% price change compared with +19.5% for PRAX. Praxis Precision Medicines is the larger company by market cap ($8.40 billion vs $7.96 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PRAX | SMMT |
|---|---|---|
| Share price | $300.43 | $9.95 |
| Market cap | $8.40B | $7.96B |
| 1-day change | -3.37% | -5.87% |
| YTD return | +1.93% | -43.11% |
| 1-year return | +76.93% | -38.54% |
| 5-year return | +19.50% | +92.83% |
| EPS (TTM) | $-12.82 | $-1.06 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | — |
| Revenue growth (YoY) | -100.00% | — |
| Net income (latest FY) | $-303.27M | $-1.08B |
| 52-week high | $392.70 | $29.23 |
| 52-week low | $167.32 | $9.89 |
| Distance from 52-week high | -23.50% | -65.96% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +124.49% | +189.15% |
| Average volume | 479.87K | 6.68M |
| Shares outstanding | 27.95M | 799.76M |
| Employees | 168 | 265 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PRAX has outperformed SMMT by 115.5 percentage points over the past year.
About Praxis Precision Medicines
PRAX stock →Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States. The company's platforms include Cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and Solidus to discover and develop antisense oligonucleotide.
Health Care · Biotechnology: Pharmaceutical Preparations · 168 employees
About Summit Therapeutics
SMMT stock →Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC).
Health Care · Biotechnology: Pharmaceutical Preparations · 265 employees
PRAX vs SMMT FAQ
Which is bigger, Praxis Precision Medicines or Summit Therapeutics?
Praxis Precision Medicines (PRAX) is larger, with a market capitalization of $8.40B compared with $7.96B for Summit Therapeutics (SMMT).
Which stock has performed better over the past year, PRAX or SMMT?
PRAX returned +76.93% over the past 12 months, compared with -38.54% for SMMT (price return, excluding dividends). Past performance does not predict future results.
Are Praxis Precision Medicines and Summit Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.